The findings of this study suggest that the CGJ-specific compound DPP could be a novel PPARα/γ dual agonist; however, further studies are warranted to examine its therapeutic potential in various metabolic disorders linked with PPARα/γ dysregulation. The gene discussed is PPARA; the disease is Other metabolic disease.